CN103242332B - 1-N acyl substituted indolone derivatives - Google Patents
1-N acyl substituted indolone derivatives Download PDFInfo
- Publication number
- CN103242332B CN103242332B CN201310175058.5A CN201310175058A CN103242332B CN 103242332 B CN103242332 B CN 103242332B CN 201310175058 A CN201310175058 A CN 201310175058A CN 103242332 B CN103242332 B CN 103242332B
- Authority
- CN
- China
- Prior art keywords
- dialdehyde
- contracting
- bromo indole
- indole ketone
- acyl substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Indole Compounds (AREA)
Abstract
The invention belongs to technical field of medicine synthesis, the present invention relates to new 1-N acyl substituted indolone derivatives and its preparation method and application.The present invention is exactly using 4-bromaniline as starting raw material, passes through into oxime, cyclisation, acetal protection, N-alkylated reaction obtain having the 1-N acyl substituted indolone derivatives of potential source biomolecule activity first.
Description
Technical field
The invention belongs to compou nd synthesis field, particularly relate to indolone derivatives and synthetic method thereof and application.
Technical background
Isatin (isatin), have another name called istain, istain has various good biological activity, as anti-convulsant activity, antiepileptic activity, antidepressant activity, Antianxiety Activity, activity of fighting against senium, anti-tumor activity, anti-microbial activity etc., be extensively studied in its research at various medicine, improvement and optimization.Be a kind of important natural product, be distributed widely in animals and plants and human body.Isatin and derivative thereof have multiple biological activity, and isatin can synthesize as industrial goods at present in a large number, are relatively cheap raw materials.Its 1, polytype chemical reaction can occur for prosposition and phenyl ring, and the synthesis for its derivative provides wide space, and therefore current is that the synthesis of the organic synthesis of substrate or isatin and derivative thereof and active research are very active with isatin.
Description
The invention provides a kind of 1-N acyl substituted indolone derivatives and synthetic method thereof and application.
Concrete technical scheme is as follows:
1-N acyl substituted indolone derivatives, structure is as follows:
x represents any one in acyl group.
X be 4-chlorobenzene formacyl, benzoyl, 4-TRIFLUOROMETHYLBENZOYL, 4-methyl benzoyl, 4-fluoro benzoyl, 2-naphthoyl any one; R is hydrogen or bromine.
Corresponding compound is:
A) 1-(4-chlorobenzene formacyl)-(3,3-contracting dialdehyde)-5 bromo indole ketone
B) 1-benzoyl-(3,3-contracting dialdehyde)-5 bromo indole ketone
C) 1-(4-TRIFLUOROMETHYLBENZOYL)-(3,3-contracting dialdehyde)-5 bromo indole ketone
D) 1-(4-methyl benzoyl)-(3,3-contracting dialdehyde)-5 bromo indole ketone
E) 1-(4-fluoro benzoyl)-(3,3-contracting dialdehyde)-5 bromo indole ketone
F) 1-(2-naphthoyl)-(3,3-contracting dialdehyde)-5 bromo indole ketone
The synthetic method of above-mentioned 1-N acyl substituted indolone derivatives, comprises the following steps: using 4-bromaniline as starting raw material, passes through into oxime, cyclisation, acetal protection, N-alkylation, obtains final product 1-N acyl substituted indolone derivatives.
Concrete synthetic technology route is as follows:
The invention still further relates to aforementioned signature 1-N acyl substituted indolone derivatives and prepare the application in antitumor, antiviral or nerve protection medicine.
The invention provides 1-N acyl substituted indolone derivatives and synthetic method thereof and application, synthetic method is reliable, simple.
Figure of description
Fig. 1 embodiment 1 result figure.
Fig. 2 embodiment 2 result figure.
Fig. 3 embodiment 3 result figure.
Fig. 4 embodiment 4 result figure.
Fig. 5 embodiment 5 result figure.
Fig. 6 embodiment 6 result figure.
Fig. 7 embodiment 7 result figure.
Fig. 8 embodiment 8 result figure.
Embodiment
Embodiment 1
5-bromo indole diketone
Get 4-bromaniline 10g(0.058mol) put into 500mL round-bottomed flask, add 250mL water, add anhydrous sodium sulphate 63.56g(0.452mol under agitation) and oxammonium hydrochloride 13.24g(0.191mol), then 2mol/L hydrochloric acid soln 10mL is added, stirred at ambient temperature 5 minutes, finally adds Chloral Hydrate 10.6g(0.116mol).By reaction mixture stirring at room temperature 15 minutes, then react 2h at 90 DEG C, after reaction 2h, TLC detects raw material and disappears, and then cools under room temperature, suction filtration, vacuum-drying, obtains yellow solid 13.4g.
Getting the 40mL vitriol oil joins in 100mL round-bottomed flask, is slowly joined in the vitriol oil by the yellow solid of 13.4g at 50 DEG C, reacts 30min at adding latter 65 DEG C completely.Be cooled to room temperature after reaction terminates, be then poured in mixture of ice and water by reaction mixture, stir 30min, suction filtration obtains red solid, dry under vacuum drying oven, obtains 5-bromo indole diketone 11.4g84%.For red solid.
1H NMR(DMSO 400MHz)δ：11.137（1H,s）,7.757-7.730(1H,t),7.666-7.661(1H,d),6.891-6.870(1H,d).
Fig. 1 is shown in by concrete collection of illustrative plates.
Embodiment 2
(3,3-contracting dialdehyde)-5-bromo indole ketone
Get 5-bromo indole diketone 10.0g(0.044mol) put in 250mL round-bottomed flask, add 125mL toluene, then add ethylene glycol 13.36g(0.221mol) and p-methyl benzenesulfonic acid 1.26g(0.07mol).Water trap is used to react 6h at 130 DEG C, after reaction 6h, TLC detects raw material disappearance, be cooled to room temperature, add 50mL water, then extraction into ethyl acetate (100mL × 3), merges organic phase, anhydrous sodium sulfate drying, decompression revolves desolventizing, sherwood oil: ethyl acetate=10:1200-300 order silica column purification.Obtain (3,3-contracting dialdehyde)-5-bromo indole ketone 11.0g 91.6%.
1H-NMR(CDCl
3400MHz)δ:8.126(1H,s),7.190-7.125(2H,t),6.776-6.754(1H,t),4.587-4.554(2H,t),4.460-4.27(2H,t)。
Fig. 2 is shown in by concrete collection of illustrative plates.
Embodiment 3
1-(4-chlorobenzene formacyl)-(3,3-contracting dialdehyde)-5 bromo indole ketone
By (3, 3-contracting dialdehyde)-5-bromo indole ketone 0.50g (1.85mmol) is dissolved in dry methylene dichloride, triethylamine 0.37g (7.40mmol) is added under ice bath, parachlorobenzoyl chloride 0.38g (2.20mmol) is dropwise added after stirring 5min, room temperature reaction 4h, after TLC detection reaction is complete, the water of 15mL is added in reaction mixture, with dichloromethane extraction 3 times, merge organic relevant dry, with sherwood oil: ethyl acetate=10:1, 200 order purification by silica gel column chromatography, obtain 1-(4-chlorobenzene formacyl)-(3, 3-contracting dialdehyde)-5 bromo indole ketone, for white solid, yield 54%.
1H NMR(CDCl
3400MHz):δ/ppm 4.390-4.356(m,2H),4.534-4.501(m,2H),7.490-7.468(d,2H),7.683-7.632(m,4H),7.837-7.814(d,1H).
Fig. 3 is shown in by concrete collection of illustrative plates.
Embodiment 4
1-benzoyl-(3,3-contracting dialdehyde)-5 bromo indole ketone
By (3, 3-contracting dialdehyde)-5-bromo indole ketone 0.50g (1.85mmol) is dissolved in dry methylene dichloride, triethylamine 0.37g (7.40mmol) is added under ice bath, Benzoyl chloride 0.31g (2.20mmol) is dropwise added after stirring 5min, room temperature reaction 4h, after TLC detection reaction is complete, the water of 15mL is added in reaction mixture, with dichloromethane extraction 3 times, merge organic relevant dry, with sherwood oil: ethyl acetate=10:1, 200 order purification by silica gel column chromatography, obtain 1-benzoyl-(3, 3-contracting dialdehyde)-5 bromo indole ketone, for white solid, yield 60%.
1H NMR(CDCl
3400MHz):δ/ppm 4.387-4.365(m,2H),4.539-4.517(m,2H),7.528-7.502(t,2H),7.655-7.632(m,3H),7.749-7.735(t,2H),7.850-7.835(d,1H).
Fig. 4 is shown in by concrete collection of illustrative plates.
Embodiment 5
1-(4-TRIFLUOROMETHYLBENZOYL)-(3,3-contracting dialdehyde)-5 bromo indole ketone
By (3, 3-contracting dialdehyde)-5-bromo indole ketone 0.50g (1.85mmol) is dissolved in dry methylene dichloride, triethylamine 0.37g (7.4mmol) is added under ice bath, 4-trifluoromethyl benzoyl chloride 0.46g (2.2mmol) is dropwise added after stirring 5min, room temperature reaction 4h, after TLC detection reaction is complete, the water of 15mL is added in reaction mixture, with dichloromethane extraction 3 times, merge organic relevant dry, with sherwood oil: ethyl acetate=10:1, 200 order purification by silica gel column chromatography, obtain 1-(4-TRIFLUOROMETHYLBENZOYL)-(3, 3-contracting dialdehyde)-5 bromo indole ketone, for white solid, yield 55%.
1H NMR(CDCl
3400MHz):δ/ppm 4.385-4.351(m,2H),4.512-4.479(m,2H),7.665-7.642(t,2H),7.812-7.748(m,4H),7.926-7.902(m,1H).
Fig. 5 is shown in by concrete collection of illustrative plates.
Embodiment 6
1-(4-methyl benzoyl)-(3,3-contracting dialdehyde)-5 bromo indole ketone
By (3, 3-contracting dialdehyde)-5-bromo indole ketone 0.50g (1.85mmol) is dissolved in dry methylene dichloride, triethylamine 0.37g (7.40mmol) is added under ice bath, dropwise add methyl benzoyl chloride 0.34g (2.20mmol) after stirring 5min, room temperature reaction 4h, after TLC detection reaction is complete, the water of 15mL is added in reaction mixture, with dichloromethane extraction 3 times, merge organic relevant dry, with sherwood oil: ethyl acetate=10:1, 200 order purification by silica gel column chromatography, obtain 1-(4-methyl benzoyl)-(3, 3-contracting dialdehyde)-5 bromo indole ketone, for white solid, yield 65%.
1H NMR(CDCl
3400MHz):δ/ppm 2.482(s,2H),4.382-4.349(m,2H),4.545-4.512(m,2H),7.316-7.295(d,2H),7.666-7.609(m,4H),7.787-7.764(d,1H).
Fig. 6 is shown in by concrete collection of illustrative plates.
Embodiment 7
1-(4-fluoro benzoyl)-(3,3-contracting dialdehyde)-5 bromo indole ketone
By (3, 3-contracting dialdehyde)-5-bromo indole ketone 0.50g (1.85mmol) is dissolved in dry methylene dichloride, triethylamine 0.37g (7.40mmol) is added under ice bath, 4-fluorobenzoyl chloride 0.35g (2.2mmol) is dropwise added after stirring 5min, room temperature reaction 4h, after TLC detection reaction is complete, the water of 15mL is added in reaction mixture, with dichloromethane extraction 3 times, merge organic relevant dry, with sherwood oil: ethyl acetate=10:1, 200 order purification by silica gel column chromatography, obtain 1-(4-fluoro benzoyl)-(3, 3-contracting dialdehyde)-5 bromo indole ketone, for white solid, yield 67%.
1H NMR(CDCl
3400MHz):δ/ppm 4.330-4.364(m,2H),4.458-4.492(m,2H),7.623-7.648(t,2H),7.725-7.788(m,4H),7.886-7.909(d,1H).
Fig. 7 is shown in by concrete collection of illustrative plates.
Embodiment 8
1-(2-naphthoyl)-(3,3-contracting dialdehyde)-5 bromo indole ketone
By (3, 3-contracting dialdehyde)-5-bromo indole ketone 0.50g (1.85mmol) is dissolved in dry methylene dichloride, triethylamine 0.37g (7.40mmol) is added under ice bath, 2-naphthoyl chloride 0.43g (2.20mmol) is dropwise added after stirring 5min, room temperature reaction 4h, after TLC detection reaction is complete, the water of 15mL is added in reaction mixture, with dichloromethane extraction 3 times, merge organic relevant dry, with sherwood oil: ethyl acetate=10:1, 200 order purification by silica gel column chromatography, obtain 1-(2-naphthoyl)-(3, 3-contracting dialdehyde)-5 bromo indole ketone, for white solid, yield 51%.
1H NMR(CDCl
3400MHz):δ/ppm 4.230-4.258(m,2H),4.289-4.347(m,2H),7.239-7.242(d,3H),7.497-7.535(m,3H),7.592-7.677(m,1H),7.894-7.914(m,2H),7.985-8.157(m,1H).
Fig. 8 is shown in by concrete collection of illustrative plates.
Embodiment 9 growth inhibitory activity to tumor cell tests
IC50 i.e. half inhibiting rate, and typical curve is a S type curve.IC50 is the concentration corresponding to check sample one half for 50% inhibition concentration and cell survival amount, and half suppresses lower, illustrates that the toxicity of medicine to cell is higher.
Take off row compound solution:
A) 1-(4-chlorobenzene formacyl)-(3,3-contracting dialdehyde)-5 bromo indole ketone;
B) 1-benzoyl-(3,3-contracting dialdehyde)-5 bromo indole ketone;
C) 1-(4-TRIFLUOROMETHYLBENZOYL)-(3,3-contracting dialdehyde)-5 bromo indole ketone;
D) 1-(4-methyl benzoyl)-(3,3-contracting dialdehyde)-5 bromo indole ketone;
E) 1-(4-fluoro benzoyl)-(3,3-contracting dialdehyde)-5 bromo indole ketone;
F) 1-(2-naphthoyl)-(3,3-contracting dialdehyde)-5 bromo indole ketone;
, be adjusted to suitable concentration for subsequent use.
Get K562, HePG2 as cell to be measured, add above-claimed cpd solution measures cell IC according to ordinary method
50value.Obtain result as follows:
Result shows, 1-N acyl substituted indolone derivatives of the present invention has good suppression human liver cancer cell HePG2, K562 cell growth effect.
Embodiment 9
By a) 1-(4-chlorobenzene formacyl)-(3,3-contracting dialdehyde)-5 bromo indole ketone;
B) 1-benzoyl-(3,3-contracting dialdehyde)-5 bromo indole ketone;
C) 1-(4-TRIFLUOROMETHYLBENZOYL)-(3,3-contracting dialdehyde)-5 bromo indole ketone;
D) 1-(4-methyl benzoyl)-(3,3-contracting dialdehyde)-5 bromo indole ketone;
E) 1-(4-fluoro benzoyl)-(3,3-contracting dialdehyde)-5 bromo indole ketone;
F) 1-(2-naphthoyl)-(3,3-contracting dialdehyde)-5 bromo indole ketone;
Add common drug auxiliary material respectively, make conventional medicine tablet.
Claims (1)
- The synthetic method of 1.1-N acyl substituted indolone derivatives, comprises the following steps: using 4-bromaniline as starting raw material, passes through into oxime, cyclisation, acetal protection, N-alkylation, obtains final product 1-N acyl substituted indolone derivatives; Described 1-N acyl substituted indolone derivatives structure is as follows: , X represents any one in 4-chlorobenzene formacyl, benzoyl, 4-TRIFLUOROMETHYLBENZOYL, 4-methyl benzoyl, 4-fluoro benzoyl or 2-naphthoyl; R is hydrogen or bromine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310175058.5A CN103242332B (en) | 2013-05-13 | 2013-05-13 | 1-N acyl substituted indolone derivatives |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310175058.5A CN103242332B (en) | 2013-05-13 | 2013-05-13 | 1-N acyl substituted indolone derivatives |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410844425.0A Division CN104530065A (en) | 2013-05-13 | 2013-05-13 | 1-N acyl substituent indolone derivative application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103242332A CN103242332A (en) | 2013-08-14 |
| CN103242332B true CN103242332B (en) | 2015-11-04 |
Family
ID=48922237
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310175058.5A Expired - Fee Related CN103242332B (en) | 2013-05-13 | 2013-05-13 | 1-N acyl substituted indolone derivatives |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103242332B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1079464A (en) * | 1991-12-18 | 1993-12-15 | 阿斯特拉公司 | Treatment comprises the preparation method of the valuable indolone of illness of cholinergic function reduction and the derivative of indole dione |
| WO1994029272A1 (en) * | 1993-06-16 | 1994-12-22 | Astra Aktiebolag | 1-substituted isatin and oxindole derivatives as inhibitors of acetylcholinesterase |
| CN1350523A (en) * | 1999-05-04 | 2002-05-22 | 美国家庭用品有限公司 | Indoline derivatives as progesterohe antagonists |
-
2013
- 2013-05-13 CN CN201310175058.5A patent/CN103242332B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1079464A (en) * | 1991-12-18 | 1993-12-15 | 阿斯特拉公司 | Treatment comprises the preparation method of the valuable indolone of illness of cholinergic function reduction and the derivative of indole dione |
| WO1994029272A1 (en) * | 1993-06-16 | 1994-12-22 | Astra Aktiebolag | 1-substituted isatin and oxindole derivatives as inhibitors of acetylcholinesterase |
| CN1350523A (en) * | 1999-05-04 | 2002-05-22 | 美国家庭用品有限公司 | Indoline derivatives as progesterohe antagonists |
Non-Patent Citations (1)
| Title |
|---|
| 201310175058.5;STN;《STN Registry数据库》;20060131;1-5 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103242332A (en) | 2013-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Singh et al. | 1, 2, 3-Triazole tethered β-lactam-chalcone bifunctional hybrids: synthesis and anticancer evaluation | |
| Burmaoglu et al. | Synthesis, biological evaluation and molecular docking studies of bis-chalcone derivatives as xanthine oxidase inhibitors and anticancer agents | |
| Ronga et al. | Design, synthesis and biological evaluation of novel 4-alkapolyenylpyrrolo [1, 2-a] quinoxalines as antileishmanial agents–part III | |
| Bai et al. | Development of chalcone-O-alkylamine derivatives as multifunctional agents against Alzheimer's disease | |
| Yang et al. | Design, synthesis and cytotoxic activities of novel hybrid compounds between 2-phenylbenzofuran and imidazole | |
| Mahal et al. | Synthesis and cytotoxic activity of novel tetrahydrocurcumin derivatives bearing pyrazole moiety | |
| Bhat et al. | Bis-pyrazolines: Synthesis, characterization and antiamoebic activity as inhibitors of growth of Entamoeba histolytica | |
| Banerjee et al. | Regioselective ortho-hydroxylation of 2-arylbenzothiazole via substrate directed C–H activation | |
| CN104387412B (en) | Fluorine boron two pyrrole derivative that erlotinib is modified and Synthesis and applications thereof | |
| CN102219751B (en) | Pentadienone-containing 4-substituted quinazoline derivative, preparation method and use thereof | |
| Xu et al. | Antifungal agents. Part 4: synthesis and antifungal activities of novel indole [1, 2-c]-1, 2, 4-benzotriazine derivatives against phytopathogenic fungi in vitro | |
| Liu et al. | Synthesis and antitumor activities of novel dibenzo [b, d] furan–imidazole hybrid compounds | |
| Jarrahpour et al. | Synthesis of novel β-lactams bearing an anthraquinone moiety, and evaluation of their antimalarial activities | |
| CN103554123B (en) | Containing chromone structure pyrazoles norcantharidin derivative and preparation method thereof and application | |
| Pasha et al. | Amberlyst-15 catalyzed Povarov reaction of N-arylidene-1H-indazol-6-amines and indoles: a greener approach to the synthesis of exo-1, 6, 7, 7a, 12, 12a-hexahydroindolo [3, 2-c] pyrazolo [3, 4-f] quinolines as potential sirtuin inhibitors | |
| CN103554122B (en) | A kind of containing chromone structure pyrazoles norcantharidin derivative and preparation method thereof and application | |
| Alam et al. | Discovery of (S)-flurbiprofen-based novel azine derivatives as prostaglandin endoperoxide synthase-II inhibitors: Synthesis, in-vivo analgesic, anti-inflammatory activities, and their molecular docking | |
| Alam et al. | Synthesis and characterization of biologically active flurbiprofen amide derivatives as selective prostaglandin-endoperoxide synthase II inhibitors: In vivo anti-inflammatory activity and molecular docking | |
| CN104530056B (en) | The heterozygote of a kind of adjacent naphthoquinones and tetrazolo pyrimidine and synthetic method thereof | |
| CN106673988A (en) | Benzyl cyclohexenone derivative and preparation method and medical application thereof | |
| Khan et al. | Studies on butenolides: 2-arylidene-4-(substituted aryl) but-3-en-4-olides—synthesis, reactions and biological activity | |
| CN103242332B (en) | 1-N acyl substituted indolone derivatives | |
| Lin et al. | Structure–activity relationship study of growth inhibitory 2-styrylchromones against carcinoma cells | |
| CN104530065A (en) | 1-N acyl substituent indolone derivative application | |
| CN102827061A (en) | 5,6,7- trimethoxy indole derivative, preparation method and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20151104 Termination date: 20160513 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |